Edit
Symic Biomedical
http://www.symicbio.com/Last activity: 26.04.2019
Active - Reference to Symic Bio
Developing a library of compounds that target and protect the ECM (extracellular matrix) from illness or injury-related degradation.
Location: United States, California, San Francisco
Total raised: $27.5M
Investors 1
| Date | Name | Website |
| - | Mitsui Glo... | mitsui-glo... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 26.04.2019 | - | $11M | - |
| 27.08.2015 | Grant | $1.5M | - |
| 05.01.2015 | Series A | $15M | - |
Mentions in press and media 4
| Date | Title | Description |
| 26.04.2019 | Symic Bio Raises $11M in Financing | Symic Bio, a San Francisco, CA-based biopharmaceutical company developing novel extracellular matrix targeting drugs, raised $11m in financing. The round was led by Cell Innovation Partners (CIP), a healthcare venture fund started by ReproC... |
| 27.08.2015 | Daily funding roundup - August 27, 2015 | Yuneec bagged $60M; MediBeacon landed $22.4M; Remerge closed $3M Mobile App Retargeting startup Remerge today announced a $3 million Series A round led by Point Nine Capital, along with Valor, VC Fonds Technologie Berlin, German Startups Gr... |
| 27.08.2015 | Symic Biomedical Receives $1.5M Phase II SBIR Grant | Symic Biomedical, Inc., a San Francisco, California-based platform therapeutic company, received a $1.5M Phase II SBIR grant. The National Institutes of Health (NIH) provided the funding. The company intends to use the funds to further deve... |
| 05.01.2015 | Symic Biomedical Secures $15M in Series A Financing | Symic Biomedical, a San Francisco, California-based biotech company, secured $15m in Series A financing. The round was led by Lilly Ventures, with participation from Den Danske Forskningsfond (Denmark), Mitsui Global Investment (Japan), All... |